CMB International Securities  Equity Research Company Update
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
China Healthcare Sector
Jill Wu CFA
Sam Hu PhD
Mkt Cap (RMB mn)
Avg 3mths to (RMB mn)
52W HighLow (RMB)
Total Issued Shares (mn)
Source Bloomberg
Shareholding Structure
A-share public shareholders 6047%
H-share public shareholders 1290%
Source Bloomberg
Source Bloomberg
12-mth price performance
Source Bloomberg
Auditor Deloitte Touche Tohmatsu
Stronger-than-expected growth in Q1
 30 Apr 2021
Building cutting-edge expertise to
secure long-term growth  1 Apr 2021
Strong growth outlook in 2021 and
beyond  25 Jan 2021
Accelerated growth in 3Q20 driven by
strong performance in CDMO and
China-base lab service  30 Oct 2020
SHSZ300 (rebased)
BUY (Maintain)
(Previous TP
RMB22401)
UpDownside
 1H21 earnings beat WuXi AppTec reported 1H21 revenue of RMB1054bn
(46% YoY) accounting for 47% of our full-year estimate Such a strong
growth was underpinned by its unique end-to-end full-service platform By
segment revenue from CDMO services surged 67% YoY while China-based
lab service and clinical research  other CRO services registered 45% YoY
and 57% YoY growth respectively Due to sustained impact of COVID
pandemic as well as delays and clinical failures in clients products revenue
from US-based laboratory services decreased 16% YoY accounting for 6%
of total revenue Attributable net profit and adjusted non-IFRS net profit grew
by 88% 68% YoY to RMB2127mn RMB2448mn respectively
 CDMO services act as growth engine In 1H21 CDMO revenue rallied 67%
YoY to RMB3599mn accounting for 34% of the total revenue In 1H21 341
out of 1413 molecules were newly added into CDMO services pipeline
including 1 19 Ph III II stage project additions via win the molecule strategy
As at Jun 2021 the Company provided CDMO services for about 14% of the
indicating consistent market share gain 4 pipeline molecules went
The Company is rapidly scaling up the manufacturing of two novel small
molecules for treating COVID-19 infections for big MNCs After establishing a
JV (WuXi XDC) with WuXi Biologics the Companys ADC (antibody drug
conjugate) CDMO client number increased 57% YoY in 1H21
 Proposed new incentive scheme The Company proposed a HK2bn H
share award and trust scheme with the target of above 34% YoY revenue
growth in 2021 In addition the Company initiated a Shareholder Alignment
Incentive (SAI) scheme for senior management with the total incentive amount
up to HK75bn The incentive pools are HK1bn HK15bn HK2bn and
HK3bn if the H-share price hits HK170 HK187 HK204 HK238
respectively We think the new incentive scheme will further help align the
interests between management and shareholders
 Maintain BUY We revised up adjusted Non-IFRS net profit of FY212223E
by 8%3%3% and forecast the adjusted Non-IFRS net profit to grow
43%29%34% YoY in FY21E22E23E respectively Moreover WuXi
AppTecs diversified investment portfolio will bring significant investment
gains over the long term Considering the increased outstanding shares we
revised our 10-year DCF-based TP to RMB16806 (WACC 974% Terminal
growth 30%)
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
YoY growth (%)
YoY growth (%)
Change (%)
Consensus EPS (RMB)
Net gearing (%)
Source Company data Wind CMBIS estimates
WuXi AppTec (603259 CH)
Strong recovery continued
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 CMBIS earnings revisions
Source CMBIS estimates
Figure 2 CMBIS vs consensus
Source Bloomberg CMBIS estimates
Figure 3 Risk-adjusted DCF valuation
DCF Valuation (in Rmb mn)
EBIT(1-tax rate)
- Change in working capital
Target Debt to Asset ratio
Effective Corporate Tax Rate
 of shares
DCF per share (in RMB)
Source CMBIS estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
FY19A FY20A FY21E FY22E FY23E  YE Dec 31 (RMB mn)
FY19A FY20A FY21E FY22E FY23E
China-based laboratory
8546 11778 15547 20212  Depreciation and
CMOCDMO services
7905 10672 14193  Change in working capital
US-based laboratory
2007  Investment loss (gain)
Clinical research and other
3002  Other operating activities
38  Net cash from operating
Acquisition of subsidiaries
(89)  Other investing activities
Selling  distribution
(771) (1026) (1341)  Net cash from investing
Administrative expenses
RD expenses
(894) (1207) (1578)  Net proceeds from shares
8790  Net borrowings
Acquisition of non-controlling interests
Finance costs net
(72)  Dividends and interests paid
200  Other financing activities
Net gain from fair value
1339  Net cash from financing
Pre-tax profit
(952) (1169) (1569)  Net change in cash
(56)  Cash at the beginning of the year
8832  Cash at the end of the year
YE 31 Dec (RMB mn)
FY19A FY20A FY21E FY22E FY23E  YE 31 Dec
FY19A FY20A FY21E FY22E FY23E
Non-current assets
9561 11017 12271  China-based laboratory
761  CMOCDMO services
6717 10169 13386 16924  US-based laboratory services
Clinical research and other
Other non-current assets
7434  Others
12663 23059 20602 22246 25667  Profit  loss ratios (%)
6945  Gross margin
5120  EBITDA margin
Trade and bills receivables
7134  Pre-tax margin
Prepayments deposits
and other receivables
210  Net margin
6259  Effective tax rate
9932 11500  Balance sheet ratios
1230  Current ratio (x)
Trade and other payables
4521  Trade receivables turnover
Other current liabilities
5749  Trade payables turnover
Net debt to total equity ratio (%)
Non-current liabilities
-  Returns (%)
Other non-current liabilities
5652  ROE
357  Per share
Shareholders equity
BVPS (RMB)
Source Company data CMBIS estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities
or issuer that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities
in this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities
and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue
of this report (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve
covered in this report
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIS
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Securities Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Securities Limited (CMBIS) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary
of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIS
does not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives financial position
or special requirements  Past performance has no indication of future performance and actual events may differ materially from that which is contained in
the report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the
and strategies and encourages investors to consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIS solely for the purpose of supplying information to the clients of CMBIS or
its affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in
securities or enter into any transaction  Neither CMBIS nor any of its affiliates shareholders agents consultants directors officers or employees shall be
liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the information contained in this report  Anyone
making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable
information advices and forecasts on an AS IS basis  The information and contents are subject to change without notice CMBIS may issue other
publications having information and or conclusions different from this report  These publications reflect different assumption point-of-view and analytical
this report
on behalf of its clients from time to time Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with
and CMBIS will not assume any responsibility in respect thereof This report is for the use of intended recipients only and this publication may not be
reproduced reprinted sold redistributed or published in whole or in part for any purpose without prior written consent of CMBIS
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations
etc) of the Order and may not be provided to any other person without the prior written consent of CMBIS
For recipients of this document in the United States
CMBIS is not a registered broker-dealer in the United States  As a result CMBIS is not subject to US rules regarding the preparation of research reports
and the independence of research analysts  The research analyst who is primary responsible for the content of this research report is not registered or
qualified as a research analyst with the Financial Industry Regulatory Authority (FINRA)  The analyst is not subject to applicable restrictions under FINRA
Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report This report
is intended for distribution in the United States solely to major US institutional investors as defined in Rule 15a-6under the US Securities Exchange Act of
1934 as amended and may not be furnished to any other person in the United States Each major US institutional investor that receives a copy of this report
by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person Any US recipient of this report wishing
to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a US-registered broker-dealer
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as
defined in the Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced
by its respective foreign entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers
Regulations Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or an Institutional Investor as defined
in the Securities and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the
extent required by law Singapore recipients should contact CMBISG at 65 6350 4400 for matters arising from or in connection with the report